BTG PLC (BTG.L)
12 Feb 2016
LONDON After being vindicated in her 2014 purchase of a U.S. company with a device to prop open diseased lungs, the chief executive of British healthcare group BTG is scouring the horizon for the next promising acquisition.
LONDON Specialist medicine company BTG received a triple dose of good news on Monday as U.S. regulators approved two new treatments and a clinical trial of a novel lung device produced positive results.
* Operating profit before acquisition adjustments and reorganisation costs was £62.9m (h1 14/15: £56.8m)